An improved understanding of EGFR driver mutations leads the way to the establishment of personalized clinical therapy based on genomic and proteomic testing, which is becoming a standard of care for patients with advanced NSCLC [13–15]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.